Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Here’s Why

Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped down before the market opened on Thursday . The stock had previously closed at $14.69, but opened at $13.93. Astellas Pharma shares last traded at $14.26, with a volume of 37,675 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Astellas Pharma Stock Performance

The stock’s 50 day moving average is $14.19 and its two-hundred day moving average is $14.58. The stock has a market capitalization of $26.35 billion, a price-to-earnings ratio of 11.08 and a beta of 0.08. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16.

About Astellas Pharma

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.